The Nomination Committee has been appointed and comprises the following members:
- Helena Arcombe, appointed by the shareholder Länsförsäkringar
- Malin Ruijsenaars, appointed by the shareholders Grenspecialisten AB and LMK Forward AB
- Clas Runnberg, appointed to represent other shareholders
- Lena Mårtensson, appointed to represent Aqilion’s network of advisors
The members appoint the Chairman between themselves.
The Nomination Committee shall prepare proposals for the 2020 Annual General Meeting regarding the Chairman of the meeting, election of Board members and Chairman of the Board, the fees to be paid to the Board Chairman and the Board members, remuneration to the auditor and election of the auditor.
The Annual General Meeting of AQILION AB will be held on Wednesday, June 10, 2020, at 05.00 p.m. (CET) in Helsingborg, Sweden.
Read more about Aqilion on the company’s website www.www.aqilion.com.
For more information, please contact
Sarah Fredriksson, CEO, AQILION AB, +46 (0)70 261 4575, email@example.com
About AQILION AB
Aqilion is a Swedish life science company that identifies unique pharmaceutical projects at an early phase in the drug discovery process and develops them in preparation for clinical trials. The goal is to demonstrate the clinical and commercial potential of the medical innovation to attract industrial partners and buyers, who in turn have the capacity to continue clinical development and take the product to market. The business model is based on involvement at an early stage and close collaboration with the innovator, regardless of whether the project is initiated by an external researcher, internal development project, or industrial partner. Aqilion prefers projects aimed at niche markets. Specialty medications (high-cost, high complexity and/or high touch drugs) and orphan drugs (drugs to treat diseases so rare that they would be unprofitable to produce without government assistance) are particularly interesting. Aqilion has its headquarters in Helsingborg.
Please visit www.www.aqilion.com.